Related Experiment Video
Updated: Jun 21, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
The search for potent, small molecule NNRTIs: A review
Dhaval G Prajapati1, R Ramajayam, Mange Ram Yadav
1Pharmacy Department, Kalabhavan, The M.S. University of Baroda, Vadodara, India.
Bioorganic & Medicinal Chemistry
|July 28, 2009
Summary
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are crucial for managing HIV-1, but drug resistance is a major challenge. Research focuses on developing new NNRTIs by studying mutations in the non-nucleoside inhibitor binding pocket.
Area of Science:
- Virology
- Medicinal Chemistry
- Pharmacology
Background:
- AIDS remains a leading global pandemic, with current Highly Active Antiretroviral Therapy (HAART) facing challenges due to HIV-1 drug resistance.
- Resistance to HAART, a combination of reverse transcriptase (RT) and protease inhibitors, arises from viral mutational changes.
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are vital drugs targeting HIV-1 by binding to an allosteric site on RT.
Purpose of the Study:
- To review the historical development of NNRTIs for HIV-1 treatment.
- To highlight the ongoing need for novel small molecules within the NNRTI class for AIDS management.
- To explore strategies for overcoming NNRTI resistance through structural and mutational studies.
Main Methods:
- Review of chronological NNRTI development.
- Analysis of structural and molecular modeling studies of enzyme complexes.
- Examination of mutational studies within the non-nucleoside inhibitor binding pocket (NNIBP).
Main Results:
- NNRTIs exhibit specificity towards HIV-1, driving extensive research into second and third-generation drugs.
- Key drawbacks of NNRTIs include the rapid generation of viral resistance and pharmacokinetic issues.
- Mutational studies identified specific amino acids in the NNIBP crucial for binding and less prone to mutation, offering potential for resistance mitigation.
Conclusions:
- Despite challenges, NNRTIs remain a critical component in the therapeutic arsenal against HIV-1.
- Understanding resistance mechanisms and identifying mutation-resistant binding sites are essential for future NNRTI design.
- Continued development of novel NNRTI small molecules is necessary for effective long-term AIDS management.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...